[Treatment guideline for breast cancer and SERM-treatment].
Iwase
Hirotaka
H
Department of Breast and Endocrine Surgery Graduate School of Medical Sciences, Kumamoto University.
Yamamoto
Yutaka
Y
Kawasoe
Teru
T
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D001141:Aromatase / Q000502:physiology; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000209:etiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004967:Estrogens / Q000378:metabolism; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011960:Receptors, Estrogen / Q000378:metabolism; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004967:Estrogens; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D001141:Aromatase